secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEXGEL, INC. (NXGL)
CIK:        0001468929
Form:       8-K
Filed at:   2023-12-05T23:59:59+00:00
Accession:  0001493152-23-043659
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NexGel acquires Kenkoderm psoriasis skincare line for $546,500 initial cash plus earn-out
--------------------------------------------------------------------------------

- Initial cash payment of $546,500; earn-out up to additional $546,500 based on 2024 performance.
- Kenkoderm is profitable for trailing twelve months and expected to be immediately accretive to NXGL.
- Deal includes 3-year non-compete from Seller; Kenkoderm has 6 SKUs sold via e-commerce and Amazon.
- Acquisition closed December 1, 2023; no shareholder approval required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468929/000149315223043659/0001493152-23-043659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468929/000149315223043659/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-043659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer